ERBB2 and breast cancer: Although a few advances have been achieved in targeted therapies, such as Trastuzumab, a drug targeting the Human Epidermal Growth Factor Receptor‐2 (Her‐2), some patients would still acquire drug resistance and develop tumor progression due to the widespread molecular heterogeneity of BC.4